Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 1.86 CAD 3.91% Market Closed
Market Cap: 120.6m CAD
Have any thoughts about
Arch Biopartners Inc?
Write Note

Operating Margin
Arch Biopartners Inc

-123.7%
Current
-106%
Average
3.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-123.7%
=
Operating Profit
-5.5m
/
Revenue
4.5m

Operating Margin Across Competitors

Country CA
Market Cap 119.5m CAD
Operating Margin
-124%
Country US
Market Cap 1.2T USD
Operating Margin
14%
Country US
Market Cap 202.3B USD
Operating Margin
17%
Country US
Market Cap 166.6B USD
Operating Margin
21%
Country KR
Market Cap 67T KRW
Operating Margin
31%
Country CH
Market Cap 38.4B CHF
Operating Margin
13%
Country US
Market Cap 38.8B USD
Operating Margin
24%
Country US
Market Cap 36.3B USD
Operating Margin
14%
Country US
Market Cap 27B USD
Operating Margin
28%
Country US
Market Cap 24.1B USD
Operating Margin
20%
Country CN
Market Cap 162B CNY
Operating Margin
27%
No Stocks Found

Arch Biopartners Inc
Glance View

Market Cap
119.5m CAD
Industry
Life Sciences Tools & Services

Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

ARCH Intrinsic Value
0.29 CAD
Overvaluation 84%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-123.7%
=
Operating Profit
-5.5m
/
Revenue
4.5m
What is the Operating Margin of Arch Biopartners Inc?

Based on Arch Biopartners Inc's most recent financial statements, the company has Operating Margin of -123.7%.